A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease

To evaluate the efficacy of
tulisokibart compared with placebo as
assessed by the proportion of participants achieving clinical remission per Crohn’s Disease Activity Index score (<150) at Week 52